BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for ...

Spending on novel therapies in high-risk bladder cancer had minimal impact on Oncology Care Model payments to practices, according to this cohort study and an average performance estimation.

The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease. A new analysis of the real-world outcomes of young ...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...

When emergency physicians are faced with limited resources or extreme demand, they need to employ specific strategies to optimize resource utilization and outcomes, according to an article in the ...

FDA accelerated approval of anticancer agents. Background: Investigator-initiated trials (IITs) are the backbone of cancer center (CC) clinical programs. They are essential to early testing of drug ...

Booster third dose of SARS-CoV-2 vaccine effectively lifts the waning immune response of solid cancer patients. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does ...

Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...